Viewing data from:

STREPTOMYCIN SULFATE

ANDA

STREPTOMYCIN SULFATE | A060076 | PFIZER LABORATORIES DIV PFIZER INC

2 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Streptomycin Sulfate (2023)

Total Spending

$5.9M

Total Claims

2,513

Beneficiaries

1,682

Avg Cost/Unit

$33.11

Spending Trend

$12.1M(2019)→$7.0M(2020)→$5.8M(2021)→$8.1M(2022)→$5.9M(2023)

YoY Change:-1.0%

5yr CAGR:-11.3%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain1 active DMF4 inactive

1 active API supplier hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

SICHUAN LONG MARCH PHARMACEUTICAL CO LTDSTREPTOMYCIN SULFATE

DMF 136431998

VETERANS ADMINISTRATIONInactiveSTREPTOMYCIN

DMF 161947

PFIZER INCInactiveSTREPTOMYCIN SULFATE

DMF 133761998

GLAXOInactiveSTREPTOMYCIN SULFATE

DMF 134011998

RHONE POULENC RORER PHARMACEUTICALS INCInactiveSTREPTOMYCIN SULFATE

DMF 134851998

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Approved Prior to Jan 1, 1982

No patent or exclusivity listings for this strength.

#002 — EQ 5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

0 patents0 exclusivities▾

INJECTABLE;INJECTION | Approved: Approved Prior to Jan 1, 1982